Analysts show high confidence in Theravance Biopharma's grow...
Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.
Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To Profit
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment